In Trusts We Trust: Controlling When Your Kids Get Your Money
A $12,000 Smartphone May Already Be in Your Pocket
The First Cyber Monday Sale of 2013 Has Arrived -- in May
Market Minute: Scrutiny Awaits Heads of JPMorgan, Apple
NASDAQ: ATHX
Athersys stem cell therapy displays power as MS treatment
Athersys price target raised to $6 from $3 at Maxim
Athersys (ATHX) Pops Higher on Strong MultiStem Data in Treating MS
Athersys Presents Research Progress in Its Multiple Sclerosis Program
Orbimed lowers stake in Athersys to 3.48% from 5.56%
Athersys reports on progress in Phase 2 study of MultiStem for ischemic stroke
Athersys Reports on Progress in Phase 2 Study of MultiStem for Ischemic Stroke
Can Stem Cells Regenerate Your Portfolio? Stephen Dunn Says Yes
Athersys CEO to Present on September 24, 2012 at the Noble Financial Life Sciences Exposition
IBC Life Sciences to hsot a conference